TelyRx Holdings Inc. has seen steady price movement this week, maintaining its position in the market amidst recent financial announcements.
This week, TelyRx Holdings Inc. (TELY.TO) has remained stable, closing at C$2.45 with no significant price change. Despite the lack of major news in recent days, the company continues to attract attention due to its recent financial results and ongoing developments in its operations.
Advertisement
TelyRx Holdings Inc.
TELY.TO
TELY.TO
TelyRx Holdings Inc.
WealthAwesomeMarket cap
$65.15M
52W high
$4.25
52W low
$2.00
1W change
+0.00%
Analyst Price Targets
Based on analyst covering TELY
Wall Street analysts forecast TELY stock price to rise 144.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+144.9% Upside
Current Price
C$2.45
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TELY's historical volatility
30-Day Vol
99.4%
Annualized
90-Day Vol
95.1%
Annualized
Trend (90d)
+0.0%
Annualized drift
90d Mean
C$2.45
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.45 | C$1.74 โ C$3.45 |
| 60 trading days | C$2.45 | C$1.51 โ C$3.98 |
| 90 trading days | C$2.45 | C$1.35 โ C$4.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on TelyRx's financial performance, particularly its revenue growth in recent quarters, as well as its trading volumes, which indicate investor interest levels.
TelyRx Reports Revenue Growth Amidst Ongoing Challenges
With a revenue increase to C$22.7 million in Q2 2026, TelyRx is demonstrating growth potential, although the stock remains down 30% year-to-date.
Bull case
The company has shown impressive revenue growth in recent quarters, suggesting a positive trend in its business fundamentals. This growth could support better stock performance in the future.
Bear case
Despite the recent revenue increases, TelyRx's stock has dropped significantly this year, highlighting ongoing challenges that investors should keep in mind.
Price Action Overview
TelyRx Holdings Inc. has seen its stock remain unchanged this week, closing at C$2.45. Over the past month, the stock has experienced a decline of 9.26%, while year-to-date performance shows a significant drop of 30%. Despite these figures, the company has maintained a stable trading price, reflecting cautious optimism among investors.
Recent Company Developments
Advertisement
This week, TelyRx has not released any major news, yet it has drawn attention due to its recent financial disclosures. In its latest earnings report, TelyRx announced a revenue increase to C$22.7 million for Q2 2026, a notable rise from C$9.3 million in the same quarter last year. This upward trend in revenue indicates a positive shift in the company's operational performance.
Technical Picture
From a technical standpoint, TelyRx's stock is currently trading below its 50-day moving average of C$2.59 and its 200-day moving average of C$2.74, suggesting a bearish trend. The stock's 52-week range has been between C$2.00 and C$4.25, with only 20% of this range being utilized. The latest trading volume was 948 shares, significantly lower than the 20-day average volume of 6,632 shares, indicating reduced investor activity.
Insider Activity
No recent insider trading activity has been reported for TelyRx Holdings Inc., which may suggest a stable environment for existing shareholders.
Conclusion
TelyRx Holdings Inc. closed at C$2.45, remaining unchanged for the day. While the recent financial results show promising growth, the stock's year-to-date performance raises questions about its future trajectory. Investors should consider these factors as they evaluate their positions in TelyRx.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
